LABP Stock - Landos Biopharma, Inc.
Unlock GoAI Insights for LABP
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | $18.00M | N/A | N/A |
| Gross Profit | N/A | $-577,000 | $17.80M | $-137,000 | $-103,000 |
| Gross Margin | N/A | N/A | 98.9% | N/A | N/A |
| Operating Income | $-22,727,000 | $-40,561,000 | $-38,816,000 | $-30,676,000 | $-13,290,000 |
| Net Income | $-21,935,000 | $-37,991,000 | $-38,226,000 | $-30,144,000 | $-13,931,000 |
| Net Margin | N/A | N/A | -212.4% | N/A | N/A |
| EPS | $-3.50 | $-9.44 | $-9.50 | $-7.51 | $-3.47 |
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and eosinophilic esophagitis; NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1 (NOD-like), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and LABP-104, an orally-active and systemically bioavailable small molecule therapeutic candidate that targets LANCL2 agonist for the treatment of systemic lupus erythematosus and rheumatoid arthritis (RA). Its preclinical candidates in development include LABP-66 is an oral and small molecule NOD-like pathway agonist for the treatment of multiple sclerosis and Alzheimer's disease; LABP-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and RA; LABP-73, an oral and small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease; and LABP-111, an oral and small molecule LANCL2 pathway agonist for the treatment of nonalcoholic steatohepatitis and type 1 diabetes. The company was incorporated in 2017 and is headquartered in Blacksburg, Virginia.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| April 12th 2022 | Jefferies | Downgrade | Hold | $1.4← $30 |
Earnings History & Surprises
LABPEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2024 | May 9, 2024 | $-1.00 | $-1.43 | -43.0% | ✗ MISS |
Q1 2024 | Mar 21, 2024 | $-0.91 | $-0.99 | -8.8% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-0.79 | $-0.94 | -19.0% | ✗ MISS |
Q3 2023 | Aug 9, 2023 | $-1.10 | $-0.63 | +42.7% | ✓ BEAT |
Q2 2023 | May 12, 2023 | $-1.00 | $-0.90 | +10.0% | ✓ BEAT |
Q1 2023 | Mar 23, 2023 | $-1.50 | $-1.30 | +13.3% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-2.90 | $-2.00 | +31.0% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-3.70 | $-2.80 | +24.3% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-3.70 | $-3.70 | 0.0% | = MET |
Q1 2022 | Mar 24, 2022 | $-0.33 | $-5.20 | -1475.8% | ✗ MISS |
Q4 2021 | Nov 15, 2021 | $-4.40 | $-3.20 | +27.3% | ✓ BEAT |
Q3 2021 | Jul 29, 2021 | $-1.40 | $1.20 | +185.7% | ✓ BEAT |
Q2 2021 | May 17, 2021 | $-0.37 | $-0.38 | -2.7% | ✗ MISS |
Q1 2021 | Mar 31, 2021 | $-0.69 | $-0.91 | -31.9% | ✗ MISS |
Q3 2020 | Sep 30, 2020 | — | $-2.52 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-1.46 | — | — |
Q1 2020 | Mar 31, 2020 | — | $-1.78 | — | — |
Q4 2019 | Dec 31, 2019 | — | $-1.08 | — | — |
Latest News
Frequently Asked Questions about LABP
What is LABP's current stock price?
What is the analyst price target for LABP?
What sector is Landos Biopharma, Inc. in?
What is LABP's market cap?
Does LABP pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to LABP for comparison